This Article  • References  • Full text PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

The Diabetes Control and Complications Trial Research Group

JAMA. 1996;276(17):1409-1415.

Abstract
Objective.
—To examine the cost-effectiveness of alternative approaches to the management of insulin-dependent diabetes mellitus (IDDM).

Design.
—A Monte Carlo simulation model was developed to estimate the lifetime benefits and costs of conventional and intensive insulin therapy. Data were collected as part of the Diabetes Control and Complications Trial (DCCT) and supplemented with data from other clinical trials and epidemiologic studies.

Setting.
—Twenty-nine academic medical centers.

Patients.
—Persons with IDDM in the United States who meet demographic and clinical eligibility criteria for enrollment in the DCCT.

Interventions.
—Conventional vs intensive diabetes management.

Results.
—Approximately 120 000 persons with IDDM in the United States meet DCCT eligibility criteria. Implementing intensive rather than conventional therapy in this population would result in a gain of 920000 years of sight, 691 000 years free from end-stage renal disease, 678 000 years free from lower extremity amputation, and 611 000 years of life at an additional cost of $4.0 billion over the lifetime of the population. The incremental cost per year of life gained is $28 661.

Conclusions.
—Over a lifetime, DCCT-defined intensive therapy reduces complications, improves quality of life, and can be expected to increase length of life. From a health care system perspective, intensive therapy is well within the range of cost-effectiveness considered to represent a good value.

Footnotes
A complete listing of the Diabetes Control and Complications Trial Research Group is available in Arch Ophthalmol. 1995;113:49-51.

Corresponding author: David M. Nathan, MD, Diabetes Unit-Bulfinch 408, Massachusetts General Hospital, 32 Fruit Street, BUL 405, Boston, MA 02114-2698. Reprints: The DCCT Research Group, Box NDIC/ DCCT, Bethesda, MD 20892.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cost-Effectiveness of Aliskiren in Type 2 Diabetes, Hypertension, and Albuminuria
Delea et al.
J. Am. Soc. Nephrol. 2009;20:2205-2213.
ABSTRACT | FULL TEXT  

Using Clinical Information To Project Federal Health Care Spending
Huang et al.
Health Aff (Millwood) 2009;28:w978-w990.
ABSTRACT | FULL TEXT  

Progress in Diabetes Research--What's Next
Nathan
JAMA 2009;301:1599-1601.
FULL TEXT  

The Effect of Comorbid Illness and Functional Status on the Expected Benefits of Intensive Glucose Control in Older Patients with Type 2 Diabetes: A Decision Analysis
Huang et al.
ANN INTERN MED 2008;149:11-19.
ABSTRACT | FULL TEXT  

A Feasibility Study of a Culturally Tailored Diabetes Intervention for Mexican Americans
Vincent et al.
Biol Res Nurs 2007;9:130-141.
ABSTRACT  

Developing a Church-Based Diabetes Prevention Program With African Americans: Focus Group Findings
Boltri et al.
The Diabetes Educator 2006;32:901-909.
ABSTRACT | FULL TEXT  

Insulin Treatment and the Problem of Weight Gain in Type 2 Diabetes
Carver
The Diabetes Educator 2006;32:910-917.
ABSTRACT | FULL TEXT  

Self-Care Autonomy and Outcomes of Intensive Therapy or Usual Care in Youth with Type 1 Diabetes
Wysocki et al.
J Pediatr Psychol 2006;31:1036-1045.
ABSTRACT | FULL TEXT  

Feasibility test of a shared care network for children with type 1 diabetes mellitus.
King et al.
The Diabetes Educator 2006;32:723-733.
ABSTRACT | FULL TEXT  

Perceived Barriers to Care and Attitudes about Vision and Eye Care: Focus Groups with Older African Americans and Eye Care Providers.
Owsley et al.
IOVS 2006;47:2797-2802.
ABSTRACT | FULL TEXT  

Health Care and Patient-Reported Outcomes: Results of the cross-national Diabetes Attitudes, Wishes and Needs (DAWN) study.
Rubin et al.
Diabetes Care 2006;29:1249-1255.
ABSTRACT | FULL TEXT  

The Epidemiology of Eye Disease: From Glycemia to Genetics The Friedenwald Lecture
Klein and Klein
IOVS 2006;47:1747-1753.
FULL TEXT  

Intensive diabetes treatment and cardiovascular disease.
Weissman et al.
NEJM 2006;354:1751-1752.
FULL TEXT  

Improvements in Diabetes Processes of Care and Intermediate Outcomes: United States, 1988-2002
Saaddine et al.
ANN INTERN MED 2006;144:465-474.
ABSTRACT | FULL TEXT  

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes
The Diabetes Control and Complications Trial/Epide
NEJM 2005;353:2643-2653.
ABSTRACT | FULL TEXT  

Quality of Care of Medicare Patients With Diabetes in a Metropolitan Fee-for-Service Primary Care Integrated Delivery System
Hollander et al.
American Journal of Medical Quality 2005;20:344-352.
ABSTRACT  

Cost-Effectiveness of Full Medicare Coverage of Angiotensin-Converting Enzyme Inhibitors for Beneficiaries with Diabetes
Rosen et al.
ANN INTERN MED 2005;143:89-99.
ABSTRACT | FULL TEXT  

The Effect of Rosiglitazone on Overweight Subjects With Type 1 Diabetes
Strowig and Raskin
Diabetes Care 2005;28:1562-1567.
ABSTRACT | FULL TEXT  

Point: Self-Monitoring of Blood Glucose in Type 2 Diabetic Patients not Receiving Insulin: The sanguine approach
Ipp et al.
Diabetes Care 2005;28:1528-1530.
FULL TEXT  

The Cost-Effectiveness of Lifestyle Modification or Metformin in Preventing Type 2 Diabetes in Adults with Impaired Glucose Tolerance
Herman et al.
ANN INTERN MED 2005;142:323-332.
ABSTRACT | FULL TEXT  

The growing volume of diabetes-related dialysis: a population based study
Lok et al.
Nephrol Dial Transplant 2004;19:3098-3103.
ABSTRACT | FULL TEXT  

Guidelines for Computer Modeling of Diabetes and Its Complications
American Diabetes Association Consensus Panel
Diabetes Care 2004;27:2262-2265.
FULL TEXT  

Intravitreal Injection of Triamcinolone for Diffuse Diabetic Macular Edema
Wong et al.
Arch Ophthalmol 2004;122:1082-1082.
FULL TEXT  

Application of Economic Analysis to Diabetes and Diabetes Care
Zhang et al.
ANN INTERN MED 2004;140:972-977.
ABSTRACT | FULL TEXT  

Screening for Type 2 Diabetes Mellitus: A Cost-Effectiveness Analysis
Hoerger et al.
ANN INTERN MED 2004;140:689-699.
ABSTRACT | FULL TEXT  

Telecare for Patients With Type 1 Diabetes and Inadequate Glycemic Control: A randomized controlled trial and meta-analysis
Montori et al.
Diabetes Care 2004;27:1088-1094.
ABSTRACT | FULL TEXT  

Cost Analysis of Human Islet Transplantation for the Treatment of Type 1 Diabetes in the Swiss-French Consortium GRAGIL
Guignard et al.
Diabetes Care 2004;27:895-900.
ABSTRACT | FULL TEXT  

The Business Case for Quality: Combining Medical Literature Research with Health Plan Data to Establish Value for Nonclinical Managers
Fetterolf and West
American Journal of Medical Quality 2004;19:48-55.
ABSTRACT  

Isolated Pancreas Transplantation for Type 1 Diabetes: A Doctor's Dilemma
Nathan
JAMA 2003;290:2861-2863.
FULL TEXT  

Dealing With Complexity in Clinical Diabetes: The value of Archimedes
Kahn
Diabetes Care 2003;26:3168-3171.
FULL TEXT  

Diabetes Modeling
Herman
Diabetes Care 2003;26:3182-3183.
FULL TEXT  

Reducing Acute Adverse Outcomes in Youths With Type 1 Diabetes: A Randomized, Controlled Trial
Svoren et al.
Pediatrics 2003;112:914-922.
ABSTRACT | FULL TEXT  

The Direct Medical Cost of Type 2 Diabetes
Brandle et al.
Diabetes Care 2003;26:2300-2304.
ABSTRACT | FULL TEXT  

APOE genotype is a risk factor for neuropathy severity in diabetic patients
Bedlack et al.
Neurology 2003;60:1022-1024.
ABSTRACT | FULL TEXT  

Trends in the Diabetes Quality Improvement Project Measures in Maine From 1994 to 1999
McClain et al.
Diabetes Care 2003;26:597-601.
ABSTRACT | FULL TEXT  

Implications of the Diabetes Control and Complications Trial
Diabetes Care 2003;26:s25-27.
FULL TEXT  

Valuing Health-Related Quality of Life in Diabetes
Coffey et al.
Diabetes Care 2002;25:2238-2243.
ABSTRACT | FULL TEXT  

Task Force #2--the cost of prevention: can we afford it? Can we afford not to do it?
Krumholz et al.
J Am Coll Cardiol 2002;40:603-615.
FULL TEXT  

Estimating Utility Values for Health States of Type 2 Diabetic Patients Using the EQ-5D (UKPDS 62)
Clarke et al.
Med Decis Making 2002;22:340-349.
ABSTRACT  

Restricted islet-cell reactive T cell repertoire of early pancreatic islet infiltrates in NOD mice
Baker et al.
Proc. Natl. Acad. Sci. USA 2002;99:9374-9379.
ABSTRACT | FULL TEXT  

Cost-effectiveness of Intensive Glycemic Control, Intensified Hypertension Control, and Serum Cholesterol Level Reduction for Type 2 Diabetes
The CDC Diabetes Cost-effectiveness Group
JAMA 2002;287:2542-2551.
ABSTRACT | FULL TEXT  

The Impact of Clinical Trials on the Treatment of Diabetes Mellitus
Nathan
J. Clin. Endocrinol. Metab. 2002;87:1929-1937.
ABSTRACT | FULL TEXT  

The Epidemiology of Complications
Bloomgarden
Diabetes Care 2002;25:924-932.
FULL TEXT  

A Diabetes Report Card for the United States: Quality of Care in the 1990s
Saaddine et al.
ANN INTERN MED 2002;136:565-574.
ABSTRACT | FULL TEXT  

Blood pressure control and diabetic retinopathy
Klein and Klein
Br J Ophthalmol 2002;86:365-367.
FULL TEXT  

Productivity and Medical Costs of Diabetes in a Large Employer Population
Ramsey et al.
Diabetes Care 2002;25:23-29.
ABSTRACT | FULL TEXT  

Management of diabetes: are doctors framing the benefits from the wrong perspective?
Wolpert and Anderson
BMJ 2001;323:994-996.
FULL TEXT  

Health Care Use of Individuals With Diabetes in an Employer-Based Insurance Population
Laditka et al.
Arch Intern Med 2001;161:1301-1308.
ABSTRACT | FULL TEXT  

Effect of Improved Glycemic Control on Health Care Costs and Utilization
Wagner et al.
JAMA 2001;285:182-189.
ABSTRACT | FULL TEXT  

Diabetes Prevention: How About NOW?
Levetan
Clin. Diabetes 2001;19:34-38.
FULL TEXT  

Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41)
Gray et al.
BMJ 2000;320:1373-1378.
ABSTRACT | FULL TEXT  

Coping skills training was effective in adolescents with type 1 diabetes
Weinger
Evid. Based Ment. Health 1999;2:111-111.
FULL TEXT  

Coping skills training reduced haemoglobin A1c and improved self efficacy in youths with diabetes
Weinger
Evid. Based Nurs. 1999;2:115-115.
FULL TEXT  

Treatment of Diabetic Retinopathy
Ferris et al.
NEJM 1999;341:667-678.
FULL TEXT  

Spectroscopic and Clinical Aspects of Noninvasive Glucose Measurements
Khalil
Clin. Chem. 1999;45:165-177.
ABSTRACT | FULL TEXT  

The Cost-effectiveness of Screening for Type 2 Diabetes
The CDC Diabetes Cost-Effectiveness Study Group
JAMA 1998;280:1757-1763.
ABSTRACT | FULL TEXT  

Health Economic Benefits and Quality of Life During Improved Glycemic Control in Patients With Type 2 Diabetes Mellitus: A Randomized, Controlled, Double-Blind Trial
Testa and Simonson
JAMA 1998;280:1490-1496.
ABSTRACT | FULL TEXT  

Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40
UK Prospective Diabetes Study Group
BMJ 1998;317:720-726.
ABSTRACT | FULL TEXT  

Clinical and Economic Impact of Implementing a Comprehensive Diabetes Management Program in Managed Care
Rubin et al.
J. Clin. Endocrinol. Metab. 1998;83:2635-2642.
ABSTRACT | FULL TEXT  

Cost-effectiveness of Chemoprophylaxis After Occupational Exposure to HIV
Frothingham et al.
Arch Intern Med 1998;158:1470-1472.
FULL TEXT  

Factors Influencing Preconception Control of Glycemia in Diabetic Women
Casele and Laifer
Arch Intern Med 1998;158:1321-1324.
ABSTRACT | FULL TEXT  

Persistently poor pregnancy outcomes in women with insulin dependent diabetes
Simmons
BMJ 1997;315:263-264.
FULL TEXT  

Cost-effectiveness of Intensive Insulin Therapy in the Diabetes Control and Complications Trial
Narayan
JAMA 1997;277:374-374.
ABSTRACT  

IS INTENSIVE DIABETES CONTROL COST-EFFECTIVE?
JWatch General 1996;1996:6-6.
FULL TEXT